On April 27, 2021 Infinity Pharmaceuticals, Inc. (NASDAQ: INFI), a clinical-stage biotechnology company developing eganelisib, a potentially first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic which addresses a fundamental biologic mechanism of immune suppression in cancer, reported that management will participate in a fireside chat at the 7th Annual Truist Securities Life Sciences Summit which is being held virtually Tuesday, May 4th – Wednesday, May 5th, 2021 (Press release, Infinity Pharmaceuticals, APR 27, 2021, View Source [SID1234578568]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Presentation details are as follow:
Truist Securities Life Sciences Summit:
Date:
Tuesday, May 4
Time:
10:30 am Eastern Time
Webcast:
The webcast of the presentation can be accessed in the Investors/Media section of Infinity’s website at www.infi.com and will be available on Infinity’s website for 30 days following the event.